Inivata Natera Files Second Patent Infringement Suit Against NeoGenomics Subsidiary Inivata The suit was filed the same day Natera received a new patent covering its patient-specific residual cancer testing and monitoring methods. NeoGenomics Shows Signs of Positive Rebound in Q2 After Earlier Missteps Premium Company leaders said that practical steps are being taken to recover from earlier underperformance and support planned growth in NGS and residual disease testing. New Data Further Validates Inivata's MRD Test as Company Prepares Commercial Launch Premium The firm has submitted data to the Centers for Medicare and Medicaid Services' MolDx program to pursue reimbursement. Princess Margaret Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies Inivata's InVisionFirst-Lung and RaDaR assays will support studies of the use of liquid biopsies in early and minimal residual disease detection. F-Star Therapeutics to Use Inivata's RaDaR Assay in Clinical Studies F-star will use the ctDNA assay to identify potential early biomarkers of clinical efficacy and evaluate treatment response for late-stage solid tumors. Apr 28, 2021 Agendia to Distribute Inivata Liquid Biopsy Breast Cancer Test in North America, Europe Feb 4, 2021 Inivata Raises $35M in Second Close of Series C Financing Round Jan 20, 2021 Natera Sues Inivata, Alleging Infringement of Cancer Testing Patents Dec 18, 2020 UK Launches Public-Private iDx-Lung Consortium to Improve Early Detection of Lung Cancers Oct 29, 2020 Maverick Therapeutics to Use Inivata's Liquid Biopsy Assay in Phase I/II Clinical Study Sep 25, 2020 People in the News: New Appointments at Inivata, Exact Sciences, Euformatics, More Jul 28, 2020 NeoGenomics Expects Q3 Revenue Growth as it Expands Liquid Biopsy Offerings, COVID-19 Testing Premium Jul 2, 2020 New Products Posted to GenomeWeb: Twist Bioscience, NeoGenomics, Flagship Biosciences Jun 25, 2020 Inivata Demonstrates Potential of ctDNA Assay for Cancer Recurrence, MRD Applications Premium May 26, 2020 NeoGenomics, Inivata Partner to Commercialize Lung Cancer Liquid Biopsy Test Apr 23, 2020 Inivata Expects New Minimal Residual Disease, Recurrence Assay to Support Pharma Trials Premium Oct 29, 2019 Inivata to Employ Liquid Biopsy Test in EORTC Phase II NSCLC Study of Lorlatinib Oct 14, 2019 Inivata Collecting Evidence for Liquid Biopsy in Immunotherapy Prediction, Response Monitoring Premium Jul 18, 2019 Inivata to Test Liquid Biopsy Against Tissue Sequencing in French Prospective Clinical Trial Jul 16, 2019 IPS Genomix to Distribute Inivata's Tests in Middle East, Africa Apr 26, 2019 Inivata Clinical Validation Bolsters Liquid Biopsy Evidence Base, Aids Platform Comparisons Premium Mar 28, 2019 Inivata Completes £39.8M Series B Funding Round Mar 5, 2019 Inivata Medicare Local Coverage Decision Finalized for InVisionFirst-Lung Liquid Biopsy Sep 13, 2018 Inivata Gets Draft Medicare Local Coverage Determination for Lung Cancer Test Jun 1, 2018 Addario Lung Cancer Medical Institute, WUSTL Launch ctDNA Clinical Study Load More Breaking News Gastric Cancer Chemotherapy Response, Prognoses Predicted With Blood-Based Immune Proteomics International Commission to Expand Molecular Testing Access for Cancer Patients NYU Langone Perlmutter Cancer Center to Validate Biological Dynamics Pancreatic Cancer Test SomaLogic Expands Into Middle East With Proteomics Supply Deal for Group 42 Healthcare Arima Genomics to Offer NGS-Based Gene Fusion Test Through Protean BioDiagnostics CLIA Lab The Scan Drug Response Variants May Be Distinct in Somatic, Germline Samples Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline. Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine. Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures. Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.